RESUMO
Exposure to diesel exhaust is a suspected risk factor for human lung cancer. The carbonaceous core of the soot particles found in diesel exhaust and the condensed organic compounds adsorbed (or bound) onto the surface of the particles are both possible contributors to this suspected risk. The extent and rate at which organic procarcinogens desorb from soot particles in the lungs after environmental and workplace exposures and the degree of metabolic activation in the lungs are also not known. We explored the relationship between a model polynuclear aromatic hydrocarbon (PAH)* and a typical carrier particle by measuring the rate of release, extent of release, and metabolic fate of benzo[a]pyrene (BaP) bound onto the carbonaceous core of diesel soot after bolus aerosol exposures of the dog's peripheral lung and trachea. Exogenous BaP was bound onto preextracted diesel soot at a surface concentration corresponding to 25% of a monomolecular layer. After deposition in the alveolar region, a fraction of BaP was rapidly desorbed from the soot and quickly absorbed into the circulating blood. Release rates then decreased drastically. When the BaP coating reached approximately 16% of a monolayer, it was not bioavailable and remained on the particles after 5.6 months in the lung. The bioavailability of BaP on particles retained in lymph nodes was markedly higher, however: after 5.6 months the surface coating of BaP was reduced to 10% of a monolayer. Fractions of BaP that remained bound to the soot surface during this 5.6 months had a low reactivity-nearly 30% of the radioactive compounds extracted from recovered soot particles were still BaP, the parent compound. In contrast, the rapidly released fraction of BaP, which was quickly absorbed through the alveolar epithelium after inhalation, appeared mostly unmetabolized in the circulation, along with low concentrations of phase I and phase II BaP metabolites. Within approximately 1 hour, however, this rapidly absorbed fraction of BaP was metabolized, most likely in the liver, with the metabolite spectrum being dominated by conjugated phase II metabolites. The fraction of BaP desorbed from particles deposited on the epithelium of the conducting airways was absorbed by the epithelium but slowly penetrated the capillary bed. The absorbed BaP was rapidly metabolized in the airway epithelium, as indicated by the influx of tritiated water (3H2O) from the lungs into the circulation. The results suggest that the dosimetry of inhaled, highly lipophilic BaP during typical exposures is bimodal. The larger fraction of bioavailable BaP deposited in the alveolar region was absorbed mostly unaltered into the blood through the alveolar type I cells and was metabolized systemically. A smaller fraction of bioavailable BaP was deposited on the airway mucosa and rapidly metabolized, most likely in the airway epithelium. The substrate levels of BaP in the epithelium of the conducting airways exceeded the systemic levels by up to two orders of magnitude. This dramatic site-of-entry to systemic duality in the dosimetry of inhaled BaP is likely to be similar in most mammalian species and should be considered in risk assessment models for PAHs in humans.
Assuntos
Benzo(a)pireno/farmacocinética , Carbono/química , Carcinógenos/farmacocinética , Alvéolos Pulmonares/efeitos dos fármacos , Traqueia/efeitos dos fármacos , Emissões de Veículos/análise , Animais , Benzo(a)pireno/toxicidade , Disponibilidade Biológica , Carcinógenos/toxicidade , Cães , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Técnicas In Vitro , Exposição por Inalação , Taxa de Depuração Metabólica , Alvéolos Pulmonares/metabolismo , Distribuição Tecidual , Traqueia/metabolismoRESUMO
Exposure to diesel exhaust may contribute to lung cancer in humans. It remains unclear whether the carbonaceous core of the soot particle or its coat of adsorbed/condensed organics contributes most to cancer risk. Equally unclear are the extent and rate at which organic procarcinogens desorb from soot particles in the lungs following inhalation exposure and the extent of their metabolic activation in the lungs. To explore the basic relationship between a model polycyclic aromatic hydrocarbon (PAH) and a typical carrier particle, we investigated the rate and extent of release and metabolic fate of benzo[a]pyrene (BaP) adsorbed on the carbonaceous core of diesel soot. The native organic content of the soot had been denuded by toluene extraction. Exogenous BaP was adsorbed onto the denuded soot as a surface coating corresponding to 25% of a monomolecular layer. Dogs were exposed by inhalation to an aerosol bolus of the soot-adsorbed BAP: Following deposition in the alveolar region a fraction of BaP was rapidly desorbed from the soot and quickly absorbed into the circulation. Release rates then decreased drastically. When coatings reached approximately 16% of a monolayer the remaining BaP was not bioavailable and was retained on the particles after 5.6 months in the lung. However, the bioavailability of particles transported to the lymph nodes was markedly higher; after 5.6 months the surface coating of BaP was reduced to 10%. BaP that remained adsorbed on the soot surface after this period was approximately 30% parent compound. In contrast, the rapidly released pulse of BaP, which was quickly absorbed through the alveolar epithelium after inhalation, appeared mostly unmetabolized in the circulation, along with low concentrations of phase I and phase II BaP metabolites. However, within approximately 1 h this rapidly absorbed fraction of BaP was systemically metabolized into mostly conjugated phase II metabolites. The results indicate that absorption through the alveolar epithelium is an important route of entry to the circulation of unmetabolized PAHS:
Assuntos
Benzo(a)pireno/farmacocinética , Carbono/química , Carcinógenos/farmacocinética , Alvéolos Pulmonares/metabolismo , Emissões de Veículos/análise , Adsorção , Animais , Disponibilidade Biológica , Cães , Exposição por InalaçãoRESUMO
The carcinogenicity of 1,3-butadiene (BD) varies greatly in the rodent species in which 2-year bioassay studies were completed. This raises the question of whether the risk of BD exposure in humans is more like that of the sensitive species, the mouse, or more like that of the resistant species, the rat. Numerous studies have indicated that one reason for the species differences in response to BD is that the blood and tissues of BD-exposed mice contain high levels of both the mono- and the diepoxide metabolite, while the tissue and blood of exposed rats contain very little of the diepoxide. The diepoxide is far more mutagenic than the monoepoxide, and so it is reasonable that the diepoxide plays a major role in tumor induction in the mouse. If the diepoxide is the primary carcinogen, the presence of the diepoxide in the blood of exposed individuals should be an indicator of risk from BD exposure. In this study, we report that the diepoxide is sufficiently stable to be excreted into the urine of exposed rodents and that the urinary levels of the diepoxide reflect the relative levels of the compound in the blood of the two species. The conclusion is that urinary diepoxide should be investigated as a potential biomarker of the formation of the diepoxide in humans exposed to BD.
Assuntos
Butadienos/farmacocinética , Carcinógenos/farmacocinética , Compostos de Epóxi/sangue , Compostos de Epóxi/urina , Animais , Biomarcadores/urina , Cromatografia Gasosa-Espectrometria de Massas , Masculino , Camundongos , Camundongos Endogâmicos , Ratos , Ratos Sprague-Dawley , Especificidade da EspécieRESUMO
Chemopreventive retinoids may be more effective if delivered to the lung epithelium by inhalation. 13-cis-Retinoic acid (13-cis-RA) was comparable to all-trans-retinoic acid (RA) in inducing transglutaminase II (TGase II) in cultured human cells. Inhaled 13-cis-RA had a significant stimulatory activity on TGase II in rat lung (P < 0.001) but not in liver tissue (P < 0.544). Furthermore, inhaled 13-cis-RA at daily deposited doses of 1.9 mg/kg/day up-regulated the expression of lung retinoic acid receptors (RARs) alpha, beta, and gamma at day 1 (RARalpha by 3.4-fold, RARbeta by 7.2-fold, and RARgamma by 9.7-fold) and at day 17 (RARalpha by 4.2-fold, RARbeta by 10.0-fold, and RARgamma by 12.9-fold). At a lower aerosol concentration, daily deposited doses of 0.6 mg/kg/day were also effective at 28 days. Lung RARalpha was induced by 4.7-fold, RARbeta by 8.0-fold, and RARgamma by 8.1-fold. Adjustment of dose by exposure duration was also effective; thus, inhalation of an aerosol concentration of 62.2 microg/liter, for durations from 5 to 240 min daily for 14 days, induced all RARs from 30.6- to 74-fold at the shortest exposure time. None of the animals exposed to 13-cis-RA aerosols showed RAR induction in livers. By contrast, a diet containing pharmacological RA (30 microg/g of diet) failed to induce RARs in SENCAR mouse lung, although it induced liver RARs (RARalpha, 21.8-fold; RARbeta, 13.5-fold; RARgamma, 12.5-fold); it also failed to induce lung TGase II. A striking increase of RARalpha expression was evident in the nuclei of hepatocytes. Pharmacological dietary RA stimulated RARalpha, RARbeta, and RARgamma as early as day 1 by 2-, 4-, and 2.1-fold, respectively, without effect on lung RARs. Therefore, 13-cis-RA delivered to lung tissue of rats is a potent stimulant of lung but not liver RARs. Conversely, dietary RA stimulates liver but not lung RARs. These data support the concept that epithelial delivery of chemopreventive retinoids to lung tissue is a more efficacious way to attain up-regulation of TGase II and the retinoid receptors and possibly to achieve chemoprevention.
Assuntos
Anticarcinógenos/administração & dosagem , Isotretinoína/administração & dosagem , Fígado/efeitos dos fármacos , Pulmão/efeitos dos fármacos , Receptores do Ácido Retinoico/biossíntese , Administração por Inalação , Animais , Neoplasias da Mama/enzimologia , Dieta , Indução Enzimática/efeitos dos fármacos , Proteínas de Ligação ao GTP/biossíntese , Proteínas de Ligação ao GTP/genética , Proteínas de Ligação ao GTP/metabolismo , Humanos , Fígado/enzimologia , Fígado/metabolismo , Pulmão/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos SENCAR , Proteína 2 Glutamina gama-Glutamiltransferase , Ratos , Ratos Sprague-Dawley , Receptores do Ácido Retinoico/genética , Estimulação Química , Transglutaminases/biossíntese , Transglutaminases/genética , Transglutaminases/metabolismo , Células Tumorais Cultivadas , Regulação para Cima/efeitos dos fármacosRESUMO
In previously treated head-and-neck cancer patients, p.o. administered isotretinoin (13-cis retinoic acid) reduced the occurrence of second aerodigestive tumors, including lung tumors, but side effects made chronic therapy problematic. We reasoned that inhaled isotretinoin might provide sufficient drug to the target cells for efficacy while avoiding systemic toxicity, and we proceeded with the pilot study reported here. Male A/J mice were given single i.p. doses of urethane, a common experimental lung carcinogen, or benzo[a]pyrene (BaP) or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), putative major carcinogens in tobacco smoke. The following day, exposures to isotretinoin aerosols for 45 min daily at 1.3, 20.7, or 481 microg/l were initiated. After 2 weeks, the high dose caused severe toxicity on the snout skin, necessitating a reduction of dose frequency to twice a week. As a precaution, the mid dose was reduced to three exposures per week. The weekly total deposited doses after the dose frequency reductions were calculated to be 0.24, 1.6, and 24.9 mg/kg for the low, mid, and high doses, of which 16% was estimated to be deposited in the lungs. The weekly deposited pulmonary drug doses were calculated to be 0.01, 0.07, and 1.1% of a previously reported ineffective oral dose in urethane-treated A/J mice. After 10-16 weeks, mice were sacrificed to count areas of pulmonary hyperplasia and adenomas. For all carcinogens, the mice exposed to the high isotretinoin dose showed reductions of tumor multiplicity ranging from 56 to 80% (P < 0.005). The mid dose was associated with reductions of tumor multiplicity by 67 and 88% (P < 0.005) in BaP- and NNK-treated mice, respectively, and was tolerated until approximately 12 weeks, when both these and the high-dose mice began losing weight. The low-dose mice had nonsignificant reductions of 30% (P < 0.13) and 16% (P < 0.30) for BaP- and NNK-treated mice, respectively without any evidence of side effects. For BaP- and NNK-treated mice, numbers of hyperplastic areas directly correlated to dose level and inversely to tumor number, suggesting arrested progression. Inhaled mid-dose isotretinoin caused up-regulation of lung tissue nuclear retinoic acid receptors (RARs) relative to vehicle-exposed mice, RARalpha (3.9-fold vehicle), RARbeta (3.3-fold), and RARgamma (3.7-fold), suggesting that these receptors may be useful biomarkers of retinoid activity in this system. The encouraging results from this pilot study suggest that inhaled isotretinoin merits evaluation in people at high risk for lung cancer.
Assuntos
Anticarcinógenos/administração & dosagem , Isotretinoína/administração & dosagem , Neoplasias Pulmonares/prevenção & controle , Administração por Inalação , Animais , Anticarcinógenos/farmacocinética , Anticarcinógenos/toxicidade , Biomarcadores Tumorais/biossíntese , Carcinógenos , Relação Dose-Resposta a Droga , Isotretinoína/farmacocinética , Isotretinoína/toxicidade , Neoplasias Pulmonares/induzido quimicamente , Neoplasias Pulmonares/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos A , Tamanho da Partícula , Projetos Piloto , Receptores do Ácido Retinoico/biossínteseRESUMO
The chronic (2-yr) inhalation toxicity of 1,3-butadiene (BD), a chemical used in large quantities to make rubber and plastics, differs greatly between mice and rats. Mice develop lung tumors after exposures to concentrations as low as 6.25 ppm, whereas rats develop mammary tumors only after exposures to 1000-8000 ppm BD. Extensive research has been carried out to determine where humans fit into this susceptibility range. Species differences in rates of metabolism of BD have been noted, but inconsistencies in metabolism data from different laboratories and some problems in the fit of physiologically based pharmacokinetic (PBPK) models with experimental data have left uncertainties. The experiments reported here are intended to clarify the issue of human metabolism of BD and to determine if metabolism of BD in cynomolgus monkeys is similar enough to metabolism in humans to use in vivo data from monkeys for PBPK modeling. The results indicate that for the reactions studied (oxidation of BD to the mono- and diepoxide), BD is metabolized substantially the same in monkey and human hepatic microsomes. The human metabolism data agreed with that reported earlier when the in vitro metabolism of BD was studied at low BD concentrations. Finally, BD at high concentrations was found to inhibit the further oxidation of its metabolite, the monoepoxide. Incorporation of this information on the competition between BD and its first oxidation product for CYP2E1 should improve the fit of PBPK models.
Assuntos
Butadienos/metabolismo , Compostos de Epóxi/metabolismo , Microssomos Hepáticos/metabolismo , Animais , Relação Dose-Resposta a Droga , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Macaca fascicularis , Oxirredução , Especificidade da EspécieRESUMO
Butadiene diepoxide (BDO2), a metabolite of 1,3-butadiene (BD) and potent mutagen, is suspected to be a proximate carcinogen in the multisite tumorigenesis in B6C3F1 mice exposed to BD. Rats, in contrast to mice, do not form much BDO2 when exposed to BD, and they do not form cancers after exposure to the low levels of BD at which mice develop lung and heart tumors. Tests were planned to determine the direct carcinogenic potential of BDO2 in similarly exposed rats and mice, to see if they would develop tumors of the lung (the most sensitive target organ in BD-exposed mice) or other target tissues. The objective of the current series of studies was to assess the acute toxicity and dosimetry to blood and lung of BDO2 administered by various routes to B6C3F1 mice and Sprague-Dawley rats. The studies were needed to aid in the design of the carcinogenesis study. Initial studies using intraperitoneal injection of BDO2 were designed to determine the rate at which each of the species cleared the compound from the body; the clearance was equally fast in both species. A second study was designed to determine if the highly reactive BDO2, when deposited in the lung, would enter the bloodstream from the lung; intratracheally instilled BDO2 did enter the bloodstream, indicating that exposure via the lungs would result in BDO2 reaching other organs of the body. In a third study, rats and mice were exposed by inhalation for 6 h to 12 ppm BDO2 to determine blood and lung levels of the compound. Concentrations of BDO2 in the lung immediately after the exposure were 2 to 3 times higher than in the blood in both species (approximately 500 and 1000 pmol/g blood in the rat and mouse, respectively). As expected, mice received a higher dose/g tissue than did rats, consistent with the higher minute volume/kg body weight of the mice. The inhalation dosimetry study was followed by a histopathology study to determine the acute toxicity to rodents following a single, 6-h exposure to 18 ppm BDO2. No clinical signs of toxicity were observed; lesions were confined to the olfactory epithelium where areas of necrosis were observed. Analysis of bronchoalveolar lavage fluid did not indicate pulmonary inflammation. Based on these findings, an attempt was made to expose rats and mice repeatedly (for 7 days) to 10 and 20 ppm BDO2, but these exposure concentrations proved too toxic, due to inflammation of the nasal mucosa and occlusion of the nasal airway, a lesion that cannot be tolerated by obligate nose breathers. Finally, the toxicity of rats and mice exposed 6 h/day for 5 days to 0, 2.5, or 5.0 ppm BDO2 was determined. The repeated exposures caused no clinical signs of toxicity, nor were any lesions observed in the respiratory tract or other major organs. Therefore, the final design selected for the carcinogenesis study comprised exposing the rats and mice for 6 h/day, 5 days/week for 6 weeks to 0, 2.5, or 5.0 ppm BDO2.
Assuntos
Compostos de Epóxi/toxicidade , Mutagênicos/toxicidade , Administração por Inalação , Animais , Peso Corporal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Compostos de Epóxi/administração & dosagem , Feminino , Pulmão/efeitos dos fármacos , Pulmão/patologia , Camundongos , Camundongos Endogâmicos , Mutagênicos/administração & dosagem , Necrose , Mucosa Olfatória/efeitos dos fármacos , Mucosa Olfatória/patologia , Ratos , Ratos Sprague-Dawley , Especificidade da Espécie , Distribuição Tecidual , Testes de ToxicidadeRESUMO
1,3-Butadiene (BD), a compound used extensively in the rubber industry, is weakly carcinogenic in Sprague-Dawley rats after chronic exposures to concentrations of 1000 and 8000 ppm. Conversely, in B6C3F1 mice, tumors occur after chronic exposures to concentrations as low as 6.25 ppm. Previously, we have shown that tissue concentrations of the mutagenic BD metabolites, butadiene monoepoxide (BDO) and butadiene diepoxide (BDO2), are present in greater concentrations in mice than in rats following acute exposures to low levels (100 ppm or less). This disparity was particularly significant for the diepoxide. We hypothesized that if these epoxides are involved in the carcinogenic response of BD, then they will also be present in rat tissues at relatively high concentrations following exposures to 8000 ppm BD. In the present study, concentrations of the BD epoxides, BDO and BDO2, were determined in blood of female Sprague-Dawley rats following a single 6-h exposure and 10 repeated exposures to a target concentration of 8000 ppm BD. Concentrations of these epoxides were also determined in a number of other tissues, including the primary rat target organ-mammary gland-following 10 repeated exposures. Blood concentrations of BDO were 4030 pmol/g +/- 191 following a 6-h exposure and were 18% lower following the 10-day exposure. Blood concentrations of BDO2, following the 8000 ppm exposures, were very similar to those previously observed after exposures to 62.5 ppm BD (11 +/- 1 and 17 +/- 1 pmol/g following exposures of 6h and 6h/day for 10 days, respectively.) Concentrations of BDO ranged from 740 +/- 110 (femur) to 8990 +/- 1150 (fat) pmol/g tissue. Concentrations of BDO2 were similar among eight tissues analyzed, ranging from 5 +/- 1 (femur) to 17 +/- 3 (heart) pmol/g tissue. Tissue concentrations of butadiene monoepoxide were increased by 17- to 50-fold in tissues from rats exposed by inhalation to 8000 ppm BD as compared to tissues from rats exposed to 62.5 ppm BD. Based on earlier studies at our institute the internal dose of BD increases approximately 14-fold in the 8000 ppm-exposed rats compared to rats exposed to 62.5 ppm BD. Concentrations of butadiene diepoxide in rat tissues following an exposure to 8000 ppm BD were similar to those observed in rat tissues following exposures to 62.5 ppm BD. This study shows that pathways responsible for the accumulation of BDO2 in rats are saturated following low-level BD exposures. This suggests that the primary determinant of BD tumorigenicity in rats is not butadiene diepoxide. The high levels of BDO observed in rat mammary tissue suggest that this metabolite may be a more important determinant of BD carcinogenesis in the rat.
Assuntos
Butadienos/farmacocinética , Carcinógenos/farmacocinética , Compostos de Epóxi/metabolismo , Mutagênicos/farmacocinética , Animais , Biotransformação , Feminino , Exposição por Inalação , Ratos , Ratos Sprague-DawleyRESUMO
Enzymes of the nasal tissue, one of the first tissues to contact inhaled toxicants, are relatively resistant to induction by traditional inducers. Because tobacco smoke has been shown to induce cytochrome P450 1A1 (CYP1A1) in rat and human lung tissue, we hypothesized that it would also alter levels of xenobiotic-metabolizing enzymes in nasal mucosae. In the present study, the effect of mainstream cigarette smoke (MCS) on nasal CYP1A1, CYP1A2 and CYP2B1/2 was explored. Four groups of 30 F344 rats were exposed to MCS (100 mg total particulate matter/m3) or filtered air for 2 or 8 weeks. Western analysis of microsomes from nasal tissue of MCS-exposed rats showed an induction of CYP1A1 in respiratory and olfactory mucosae, as well as liver, kidney and lung. Relative to controls, CYP1A2 levels increased slightly in the liver and olfactory mucosa. CYP2B1/2, which increased in the liver, appeared to decrease in upper and lower respiratory tissues. Little to no immunoreactivity with CYP1A1 antibody was observed in fixed nasal sections of control rats, yet intense immunoreactivity was seen in epithelia throughout the nasal cavity of MCS-exposed rats. Ethoxyresorufin O-deethylase activity (associated with CYP1A1/2) decreased approximately 2-fold in olfactory mucosa, but increased in non-nasal tissues of rats exposed to MCS. Methoxy- and pentoxyresorufin O-dealkylase activities (associated with CYP1A2 and CYP2B1/2, respectively) decreased in olfactory and respiratory mucosae, as well as lung (CYP2B1/2), yet increased in liver. These data suggest that xenobiotic-metabolizing enzymines of the nasal mucosae may be regulated differently than other tissues.
Assuntos
Sistema Enzimático do Citocromo P-450/biossíntese , Isoenzimas/biossíntese , Mucosa Nasal/efeitos dos fármacos , Fumaça/efeitos adversos , Animais , Sistema Enzimático do Citocromo P-450/metabolismo , Indução Enzimática , Imuno-Histoquímica , Exposição por Inalação , Isoenzimas/metabolismo , Masculino , Mucosa Nasal/enzimologia , Mucosa Nasal/patologia , Plantas Tóxicas , Ratos , Ratos Endogâmicos F344 , NicotianaRESUMO
While inhaled polycyclic aromatic hydrocarbons have long been suspected to induce lung cancer in humans, their dosimetry has not been fully elucidated. A key question is whether the critical exposure occurs during absorption in the lungs, or if toxicants in the systemic circulation contribute significantly to lung cancer risk. In particular, data are needed to determine how the physical properties of inhalants affect local dosimetry in the respiratory tract. Pyrene, a tobacco smoke component, was selected for study because it has physical properties between those of highly lipophilic benzo[a]pyrene and water-soluble nitrosamines. Aliquots of 5 ng of pyrene dissolved in a phospholipid/ saline suspension were instilled as a single-spray bolus in the posterior trachea of the dog just anterior to the carina. For 3 h after instillation, blood was repeatedly sampled from the azygous vein, which drains the mucosa around the point of instillation, and from both sides of the systemic circulation. At 3 h post-instillation, tissue samples were taken. Autoradiography was used to determine the depth distribution of pyrene in the tracheal mucosa. The concentration of pyrene-equivalent radioactivity in the azygous vein peaked 9 min after the instillation. At approximately 30 min after instillation, a rapid early clearance phase shifted into a distinctly slower second clearance phase. Rates of rapid clearance were, however, sufficiently slow to indicate diffusion-limited absorption of pyrene in the trachea. This finding was corroborated by high concentrations of pyrene in the epithelium as determined by autoradiography. High epithelial concentration of pyrene combined with a slow penetration into the circulating blood allowed substantial first-pass metabolic conversion of pyrene in the tracheal mucosa. A total of 13% of the instilled pyrene was retained in the tracheal mucosa 3.2 h after instillation; of this, 29% was parent compound, 52% was organic-extractable metabolites, 14% was water-soluble metabolites and 6% (approximately 1% of the instilled amount) was covalently bound to tracheal tissues. Results support the inference that lipophilic protoxicants, because of slow, diffusion-limited absorption, are more likely than water-soluble protoxicants to be bioactivated in the lining epithelium and, in turn, induce first-pass toxicity at the site of entry. In addition, limitations were identified in the use of systemically distributed biomarkers of PAHs, such as urinary hydroxypyrene levels, as indicators of the biologically effective dose in airway target cells.
Assuntos
Biomarcadores , Compostos Policíclicos/toxicidade , Pirenos/farmacocinética , Traqueia/metabolismo , Animais , Carga Corporal (Radioterapia) , Cromatografia Líquida de Alta Pressão , Cães , Feminino , Meia-Vida , Masculino , Compostos Policíclicos/metabolismo , Pirenos/administração & dosagem , Traqueia/irrigação sanguíneaRESUMO
Lung cancer is largely a site-of-entry disease caused by inhaled carcinogenic agents, especially tobacco smoke. Two major groups of procarcinogens, tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons, are putative agents, but their relative contributions are disputed. An important indicator of relative potency for these compounds is the dose to the target epithelial cells. Although we have reported the dose of polycyclic aromatic hydrocarbons to the canine tracheal epithelium [Gerde et al., Carcinogenesis (Lond.), 18: 1825-1832, 1997; Gerde et al., Carcinogenesis (Lond.), in press, 1998], the purpose of the current study was to characterize the absorption and metabolism of low levels of one tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in the canine trachea. One hundred ng of tritiated NNK were instilled in the distal trachea of the dog. Blood was repeatedly sampled from the azygous vein and both sides of the systemic circulation from 15 s to 30 min after instillation. Tissues were then removed and analyzed for the tritiated NNK and its metabolites. Autoradiography was used to determine the depth distribution of tritium in the tracheal mucosa. Most NNK appeared rapidly in the blood draining the airway mucosa, but there was also a slow clearance phase. During absorption, NNK was distributed within the entire depth of the mucosa to the tracheal cartilage; however, a portion was conspicuously bound to the mucin component of the mucous lining layer. Reversible binding to mucin may be largely responsible for the slow clearance phase. Despite the rapid absorption of most of the tritium, NNK was nonetheless extensively metabolized in the tracheal mucosa. Systemic metabolism was also rapid: within 18 min of instillation, the NNK parent compound had disappeared from the systemic circulation, and 45 min after instillation, no NNK was found in the trachea or any distal tissue. Although the rapid absorption and distribution of NNK and its metabolites ensured widespread and extensive distal binding in all tissues, first-pass metabolism and activation of NNK in the airway mucosa were sufficiently rapid to cause levels of binding at the site of absorption to be approximately 20-fold those of distal tissues. NNK may thus act as a site-of-entry carcinogen. This observation may be important in estimating the contribution of NNK to lung cancer relative to other carcinogens and for explaining increased incidences of oral cancers in users of snuff and chewing tobacco in which NNK is present in high concentrations.
Assuntos
Carcinógenos/farmacocinética , Nitrosaminas/farmacocinética , Traqueia/metabolismo , Absorção , Administração por Inalação , Animais , Biotransformação , Carcinógenos/metabolismo , Carcinógenos/toxicidade , Cães , Epitélio/metabolismo , Feminino , Neoplasias Pulmonares/induzido quimicamente , Mucosa/metabolismo , Nitrosaminas/metabolismo , Nitrosaminas/toxicidade , Traqueia/efeitos dos fármacosRESUMO
High levels of xenobiotic-metabolizing enzymes occur in the nasal mucosa of all species studied. In certain species, including rats and rabbits, unique enzymes are present in the nasal mucosa. The function of these enzymes is not well understood, but it is thought that they play a role in protecting the lungs from toxicity of inhalants. The observation that several nasal xenobiotic-metabolizing enzymes accept odorants as substrates may indicate that these enzymes also play a role in the olfactory process. Xenobiotic-metabolizing enzymes were found in the nasal cavity around 15 years ago. Since that time, much has been learned about the nature of the enzymes and the substrates they accept. In the present review, this information is summarized with special attention to species differences in xenobiotic-metabolizing enzymes of the nasal cavity. Such differences may be important in interpreting the results of toxicity assays in animals because rodents are apparently more susceptible to nasal toxicity after exposure to inhalants than are humans.
Assuntos
Cavidade Nasal/enzimologia , Mucosa Nasal/enzimologia , Xenobióticos/metabolismo , Administração por Inalação , Animais , Sistema Enzimático do Citocromo P-450/metabolismo , Indução Enzimática , Inibidores Enzimáticos/farmacologia , Humanos , Especificidade de Órgãos , Coelhos , Ratos , Especificidade da EspécieRESUMO
While tobacco smoke has been conclusively identified as a lung carcinogen, there is much debate over which smoke constituent(s) are primarily responsible for its carcinogenicity. Previous studies in our laboratory suggested that highly lipophilic carcinogens are slowly absorbed in the thicker epithelium of the conducting airways, potentially allowing for substantial local metabolism. The bioactivation of polycyclic aromatic hydrocarbons in airway epithelium may, hence, be important in tobacco smoke-induced carcinogenesis. In the present study, the hypothesis of slow absorption and substantial local metabolic activation of highly lipophilic carcinogen in airway epithelium was tested in dogs. A single dose of tritiated benzo[a]pyrene (BaP) dissolved in a saline/phospholipid suspension was instilled in the trachea, just anterior to the carina. At intervals of a few minutes up to 30 min over a 3-h period, blood samples were drawn from the azygous vein, which drains the area around the point of instillation, and from the systemic circulation. Tissue samples were taken at the end of the experiment. The concentration of BaP with depth into the tracheal mucosa was determined with autoradiography. BaP was slowly absorbed into the trachea with a half-time of approximately 73 min, which is consistent with diffusion-limited passage through the epithelium and lead to local doses in the tracheal epithelium that were more than a 1000-fold those of other tissues. The long retention of BaP in the epithelium provided the local metabolizing enzymes with high substrate levels over a long period, resulting in extensive metabolism. At 3 h after the exposure, 23% of the BaP-equivalent activity remained in the tracheal mucosa. Of this fraction, 13% was parent compound, 28% was organic extractable, 31% was water-soluble, and 28-7% of the instilled dose was bound to tracheal tissues. These results explain the tendency of highly lipophilic carcinogens, such as BaP, to induce tumors at the site of entry and, furthermore, indicate that the highly lipophilic components of tobacco smoke and polluted air may be the most important contributors to lung tumors of the conducting airways.
Assuntos
Benzo(a)pireno/farmacocinética , Carcinógenos/farmacocinética , Traqueia/metabolismo , Absorção , Animais , Autorradiografia , Benzo(a)pireno/metabolismo , Carcinógenos/metabolismo , Cromatografia Líquida de Alta Pressão , Cães , Epitélio/metabolismo , Neoplasias Pulmonares/induzido quimicamente , RadiometriaRESUMO
1,3-Butadiene (BD), a compound used extensively in the rubber industry, is a potent carcinogen in mice and a weak carcinogen in rats in chronic carcinogenicity bioassays. While many chemicals are known to alter their own metabolism after repeated exposures, the effect of exposure prior to BD on its in vivo metabolism has not been reported. The purpose of the present research was to examine the effect of repeated exposure to BD on tissue concentrations of two mutagenic BD metabolites, butadiene monoepoxide (BDO) and butadiene diepoxide (BDO2). Concentrations of BD epoxides were compared in several tissues of rats and mice following a single exposure or ten repeated exposures to a target concentration of 62.5 ppm BD. Female Sprague-Dawley rats and female B6C3F1 mice were exposed to BD for 6 h or 6 h x 10 days. BDO and BDO2 were quantified in blood and several other tissues following preparation by cryogenic vacuum distillation and analysis by multidimensional gas chromatography-mass spectrometry. Blood and lung BDO concentrations did not differ significantly (P < or = 0.05) between the two exposure regimens in either species. Following multiple exposures to BD, BDO levels were 5- and 1.6-fold higher (P < or = 0.05) in mammary tissue and 2- and 1.4-fold higher in fat tissue of rats and mice, respectively, as compared with single exposures. BDO2 levels also increased in rat fat tissue following multiple exposures to BD. However, in mice, levels of this metabolite decreased by 15% in fat, by 28% in mammary tissue and by 34% in lung tissue following repeated exposures to BD. The finding that the mutagenic epoxide BDO, which is the precursor to the highly mutagenic BDO2, accumulates in rodent fat may be important in assessing the potential risk to humans from inhalation of BD.
Assuntos
Butadienos/toxicidade , Carcinógenos/toxicidade , Compostos de Epóxi/metabolismo , Tecido Adiposo/metabolismo , Administração por Inalação , Animais , Butadienos/administração & dosagem , Butadienos/metabolismo , Carcinógenos/administração & dosagem , Carcinógenos/metabolismo , Compostos de Epóxi/sangue , Feminino , Fêmur/metabolismo , Pulmão/metabolismo , Glândulas Mamárias Animais/metabolismo , Camundongos , Ratos , Ratos Sprague-DawleyRESUMO
Metal tritides including titanium tritide (Ti 3Hx) and erbium tritide (Er 3Hx) have been used as components of neutron generators. The current understanding of metal tritides and their radiation dosimetry for internal exposure is very limited, and the ICRP Publication 30 does not provide for tritium dosimetry in metal tritide form. However, a few papers in the literature suggest that the solubility of metal tritides could be low. The current radiation protection guidelines for metal tritide particles are based on the assumption that their biological behavior is similar to tritiated water, which could be easily absorbed into body fluid. Therefore, these particles could have relatively short biological half-lives (10 d). If the solubility is low, the biological half-life of metal tritide particles and the dosimetry of an inhalation exposure to these particles could be quite different from tritiated water. This paper describes experiments on the dissolution rate of titanium tritide particles in a simulated lung fluid. Titanium tritide particles with mean sizes of 103 microm (coarse) and 0.95 microm (fine) were used. The results showed that the coarse particles dissolved much more slowly than the fine particles. The long-term dissolution half times were 361 and 33 d for the coarse and fine particles, respectively. Dissolution data of the fine particles were consistent with the diffusion theory. The dissolution half times were longer than the 10-d biological half time for tritiated water in the body. This finding has significant implications for the current health protection guidelines, including annual limits of intakes and derived air concentrations.
Assuntos
Érbio/farmacocinética , Pulmão/metabolismo , Proteção Radiológica/normas , Titânio/farmacocinética , Trítio/farmacocinética , Líquidos Corporais/metabolismo , Érbio/química , Humanos , Modelos Biológicos , Monitoramento de Radiação/instrumentação , Monitoramento de Radiação/métodos , Análise de Regressão , Fatores de Tempo , Titânio/química , Trítio/química , UltrafiltraçãoRESUMO
A gas chromatography-mass spectrometry (GC-MS) method using isotope dilution was developed to measure trace levels of xylene metabolites in brain tissues. The primary metabolites of xylene are dimethylphenol (DMP), methylbenzyl alcohol (MBA), toluic acid (TA), and methylhippuric acid (MHA). The internal standard was a mixture of deuterated DMP-d3, TA-d7, and MHA-d7. DMP-d3 was commercially available and was used as the internal standard for both DMP and MBA. TA-d7 and MHA-d7 were biosynthesized by administering xylene-d10 to rats and collecting their urine. Based on the noise peaks in 10 blank samples, the on-column limits of quantitation (mean +10 SD of noise peaks) were approximately 305, 1220, 545, and 386 pg for DMP, MBA, TA, and MHA, respectively. Analyte detection and recovery tests from brain tissues of control rats were conducted by spiking the tissues with 32 nmol/g of each analyte, together with the deuterated metabolites. The tissues were homogenized, extracted with ethyl acetate, and derivatized by trimethylsilylation. One microliter of the sample was injected into the GC-MS. The recoveries of the analytes were 104 +/- 8%, 80 +/- 9%, 93 +/- 10%, and 92 +/- 11% (mean +/- SD, n = 7) for DMP, MBA, TA, and MHA, respectively. The tissue preparation efficiency, which was indicated by absolute recoveries of internal standards, was approximately 33% for DMP, MBA, and TA and approximately 80% for MHA. No metabolites were detected in untreated control tissues. This simple and sensitive method to simultaneously detect major xylene metabolites in brain tissues could also be used for the analysis of blood and urine samples from workers to monitor p-xylene exposure.
Assuntos
Encéfalo/metabolismo , Cromatografia Gasosa-Espectrometria de Massas/métodos , Xilenos/metabolismo , Animais , Química Encefálica , Calibragem , Deutério , Ratos , Padrões de Referência , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Xilenos/análise , Xilenos/urinaRESUMO
Two members of the cytochrome P450 2A subfamily, CYP2A10 and 2A11, are abundant nasal enzymes previously characterized in rabbit olfactory microsomes. Rabbit CYP2A is active toward a number of nasal toxicants, including the rat nasal procarcinogen hexamethylphosphoramide (HMPA). While P450s immunochemically related to the rabbit CYP2As have been detected in rat and human nasal mucosa, confirmation of these enzymes as members of the CYP2A subfamily and efforts to characterize their ability to bioactivate toxicants have been limited. In the present study, the regional distribution and cell-specific expression of CYP2A in the rat nasal cavity were examined using an antibody to rabbit CYP2A10/11. In sections of the anterior nose, immunoreactive CYP2A was present in ciliated cells of the nasal respiratory epithelium and cuboidal epithelial cells of the nasal transitional epithelium, but was absent in squamous epithelial cells. The most intense immunostaining was observed in the posterior nose. Olfactory sustentacular cells and Bowman's gland cells in sections posterior to the nasal papilla stained most intensely. Western blot analysis revealed that anti-CYP2A10/11 recognized a sharp band of approximately 50 kDa in nasal respiratory and olfactory microsomes, supporting the premise that the antibody is reacting with a cytochrome P450 enzyme. The nasal expression of CYP2A6 mRNA--a member of the human CYP2A subfamily having a high degree of homology to rabbit 2A10 and 2A11--was examined in human surgical patients. Middle turbinectomy tissues--largely composed of nasal respiratory epithelia--from 11 patients were analyzed for the presence of CYP2A6 using reverse transcription-polymerase chain reaction (RT-PCR). Identification of CYP2A6 was confirmed by DNA sequencing of RT-PCR products. CYP2A6 mRNA was detected in all of the human samples analyzed. In additional experiments, human CYP2A6 metabolized HMPA to formaldehyde, suggesting that this compound might cause nasal toxicity in humans. The identification of CYP2A cytochromes in rat and human nasal tissues may have important implications for risk assessment of inhaled xenobiotics.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Carcinógenos/farmacocinética , Sistema Enzimático do Citocromo P-450/metabolismo , Hempa/farmacocinética , Oxigenases de Função Mista/metabolismo , Mucosa Nasal/enzimologia , Animais , Biotransformação , Citocromo P-450 CYP2A6 , Sistema Enzimático do Citocromo P-450/genética , Família 2 do Citocromo P450 , Humanos , Pulmão/metabolismo , Masculino , Microssomos/metabolismo , Microssomos Hepáticos/metabolismo , Oxigenases de Função Mista/genética , Mucosa Nasal/ultraestrutura , Mucosa Olfatória/enzimologia , Mucosa Olfatória/ultraestrutura , Especificidade de Órgãos , Reação em Cadeia da Polimerase , Pró-Fármacos/farmacocinética , RNA Mensageiro/análise , Coelhos , Ratos , Ratos Endogâmicos F344 , Especificidade da EspécieRESUMO
Species differences in the metabolism of 1,3-butadiene (BD) have been studied in an effort to explain the major differences observed in the responses of mice, the sensitive species, and rats, the resistant species, to the toxicity of inhaled BD. BD is metabolized by the same metabolic pathways in all species studied, but there are major species differences in the quantitative aspects of those pathways. Of the species studied, mice are the most efficient at metabolizing BD to the initial metabolite, the monoepoxide (BDO). Mice either convert most of the BDO to the diepoxide (BDO2), the most mutagenic of the BD metabolites, or form conjugates of the BDO with glutathione (GSH). Rats, on the other hand, are less active at forming BDO, oxidize very little of the BDO to BDO2, and form GSH conjugates with either the BDO or its hydrolysis product, butenediol. Primates convert even less of inhaled BD to BDO and hydrolyze most of the BDO to the butenediol. The extent to which primates form BDO2 is unknown. Because of the association of high levels of the highly mutagenic BDO2 with the sensitive rodent strain, it is important to determine the production of this metabolite in primates, particularly humans.
Assuntos
Butadienos/metabolismo , Carcinógenos/metabolismo , Animais , Glutationa/metabolismo , Hidrólise , Camundongos , Oxirredução , Ratos , Especificidade da EspécieRESUMO
Available data suggest that: (1) the greater uptake of isoprene in mice relative to rats may not contribute to differences in sensitivity because the blood levels of total metabolites are similar in the two species; (2) in rats, saturation of blood levels of isoprene monoxide and the hydrocarbon could not be demonstrated at inhaled isoprene concentrations up to 8200 ppm, but saturation of blood levels of diols/diepoxide and of non-volatile metabolites occurred at approximately 1480 ppm (similar data are not reported for mice); (3) reaction of reactive isoprene metabolites with blood components in mice and rats is similar to reaction of butadiene metabolites in rats and much greater than that of butadiene metabolites in mice. This may contribute to the greater sensitivity of mice to butadiene carcinogenicity relative to isoprene carcinogenicity; (4) reported data do not conclusively show that differences in tissue concentrations of isoprene metabolites contribute to the differences in the relative potencies of isoprene and butadiene in mice or to the greater carcinogenic potency of isoprene in mice relative to that in rats.
Assuntos
Butadienos/metabolismo , Hemiterpenos , Pentanos , Animais , Hemoglobinas/metabolismo , Camundongos , Ratos , Especificidade da EspécieRESUMO
Levels of butadiene monoepoxide (BDO) and butadiene diepoxide (BDO2) were compared in tissues of male Sprague-Dawley rats and male B6C3F1 mice and in tissues of male and female Sprague-Dawley rats following inhalation exposures to 62.5 ppm 1,3-butadiene (BD). In male rats, BDO2 levels were highest in blood and were present at a concentration of only 5 +/- 1 pmol/g. Following a 6-h exposure, the concentration of BDO2 in the blood, femurs, lung and fat of female rats was 3 to 7-fold that of male rats. Levels of BDO were similar in tissues of female and male rats. Generally, levels of BDO were approximately 3 to 8-fold greater in mouse tissues as compared with rat tissues following 4-h exposures to BD. In blood, 204 +/- 15 pmol/g BDO2 was detected in male mice, while in rats, blood BDO2 levels were 5 +/- 1 pmol/g. This study shows marked species differences in tissue levels of BD epoxides, particularly BDO2, in rats and mice, and is the first to show gender differences in BD metabolism.